News Data readout puts J&J's bladder cancer drug back on track New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.
News J&J expecting $400m hit from tariffs in 2025 J&J chief executive Joaquin Duato has told analysts that tax policy, not tariffs, is the key to increasing pharma manufacturing capacity in the US.
News At-home tablet now an option for NHS bladder cancer patients The first targeted drug for a common form of bladder cancer that can be taken at home. J&J's Balversa, has been backed for NHS use.
News Third time not so lucky in J&J's bid to end talc liability Johnson & Johnson's third attempt to use bankruptcy proceedings to settle lawsuits claiming its talc-based products harmed consumers has failed.
News J&J throws the gauntlet down to AZ with new survival data New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.
News AZ builds in China, as J&J ramps up its US investments AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.
News NHS use of digital cardiac rehab tools endorsed Seven digital health technologies used to support people recovering from cardiovascular diseases have been recommended for use by the NHS.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
